Advertisement
Advertisement
NUVL
Nuvalent, Inc. Class A Common Stock
102.79
USDSponsored
-1.80
-1.72%
Apr 10, 15:59 UTC -4
Closed
After-Market
102.78
-0.02
-0.02%
NUVL Earnings Reports
Positive Surprise Ratio
NUVL beat 8 of 19 last estimates.
42%
Next Report
Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$1.34
Implied change from Q4 25 (Revenue/ EPS)
--
/-15.19%
Implied change from Q1 25 (Revenue/ EPS)
--
/+13.56%
Nuvalent, Inc. Class A Common Stock earnings per share and revenue
On Feb 26, 2026, NUVL reported earnings of -1.58 USD per share (EPS) for Q4 25, missing the estimate of -1.50 USD, resulting in a -4.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.57% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -1.34 USD, with revenue projected to reach -- USD, implying an decrease of -15.19% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Nuvalent, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Nuvalent, Inc. Class A Common Stock reported EPS of -$1.58, missing estimates by -4.98%, and revenue of $0.00, 0% as expectations.
How did the market react to Nuvalent, Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved down -0.57%, changed from $104.53 before the earnings release to $103.93 the day after.
When is Nuvalent, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for Nuvalent, Inc. Class A Common Stock's next earnings report?
Based on 13
analysts, Nuvalent, Inc. Class A Common Stock is expected to report EPS of -$1.34 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement